Formoterol
Active ingredient · 2 therapeutic classes
Sold as Zenhale · Duaklir Genuair · Trixeo Aerosphere
- Drug class
- Selective Beta-2-Adrenoreceptor Agonists
- Availability
- Prescription only
- Routes
- Respiratory (Inhalation)
- Markets covered
- 3
- Products on record
- 9
Overview
Plain-language summary, compiled from the cited regulatory records
Formoterol is a medication classified as a selective beta-2-adrenoreceptor agonist [1]. It is approved for the long-term maintenance treatment of bronchoconstriction in patients diagnosed with chronic obstructive pulmonary disease (COPD) [1]. This includes conditions such as chronic bronchitis and emphysema [1]. Formoterol fumarate inhalation solution is intended for twice-daily administration, taken in the morning and evening, as part of a regular treatment regimen [1].
It is important to note that formoterol fumarate inhalation solution is not intended for use in treating acute deteriorations of COPD [1]. This medication is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 2 | December 23, 2025 |
| EU European Union | EMA | 2 | September 19, 2025 |
| GB United Kingdom | MHRA | 5 | March 27, 2026 |
USUnited States· FDA
2 products
Uses
1 INDICATIONS AND USAGE Formoterol fumarate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
1 ) Important limitations of use: • Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. 2 ) •Formoterol fumarate inhalation solution is not indicated to treat asthma.
1 Maintenance Treatment of COPD Formoterol fumarate inhalation solution is indicated for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
2) ]. Formoterol fumarate inhalation solution is not indicated to treat asthma. The safety and effectiveness of formoterol fumarate inhalation solution in asthma have not been established.
EUEuropean Union· EMA
2 products
Uses
1).
How to take
GBUnited Kingdom· MHRA
5 products
5 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Drug interactions
Known interactions involving Formoterol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 423. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 07afdf7e-c480-48… · revised December 23, 2025 [PDF]
- [2]European Medicines Agency · EMEA/H/C/004983 · revised September 19, 2025
- [3]MHRA (UK) · PLPI187992442 · revised March 27, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.